Aromatic-ring-fused pyrimidine derivative
There are provided novel pyrimidine derivatives which has been fused with an aromatic heterocycle selected from thiophene, thiazole and pyridine or pharmaceutically acceptable salts thereof; and a pharmaceutical composition comprising said compound as an active ingredient. These compounds exhibit excellent promoting activity on insulin secretion and activity against hyperglycemia. Hence, the pharmaceutical compositions comprising such compounds as active ingredients, based on these actions, are useful for treating and/or preventing insulin-dependent diabetes (type 1 diabetes), non-insulin-dependent diabetes (type 2 diabetes), insulin-resistant diseases, obesity, and the like.
1. A method of inhibiting hyperglycemia comprising administering to a subject in need thereof an effective amount of the pharmaceutical composition comprising
a fused pyrimidine compound represented by Formula (I) or a pharmaceutically acceptable salt thereof:
wherein A is selected from the group consisting of
wherein the carbon atoms which form the structure A may be substituted with one or more group(s) selected from the group consisting of lower alkyl, —O-lower alkyl, halogen, carboxyl, —CO 2 -lower alkyl and carbamoyl;
—R 1 is a phenyl substituted with at least one halogen; and
—R 2 is an optionally substituted cycloamino,
and a pharmaceutically acceptable carrier or excipient.
2. The method according to claim 1 , wherein A is
wherein the carbon atoms which form the structure A may be substituted with one or more group(s) selected from the group consisting of lower alkyl, —O-lower alkyl, halogen, carboxyl, —CO 2 -lower alkyl and carbamoyl.
3. The method according to claim 1 , wherein R 1 is phenyl substituted with at least three halogens.
4. The method according to claim 3 , wherein R 2 is optionally substituted piperazino.
5. The method according to claim 3 , wherein R 2 is optionally substituted piperidino.
6. The method according to claim 1 , wherein A is
wherein the carbon atoms which form the structure A may be substituted with one or more group(s) selected from the group consisting of lower alkyl, —O-lower alkyl, halogen, carboxyl, —CO 2 -lower alkyl and carbamoyl.
7. The method according to claim 6 , wherein R 1 is phenyl substituted with at least three halogens.
8. The method according to claim 7 , wherein R 2 is optionally substituted piperazino.
9. The method according to claim 7 , wherein R 2 is optionally substituted piperidino.
10. The method according to claim 1 , wherein A is
wherein the carbon atoms which form the structure A may be substituted with one or more group(s) selected from the group consisting of lower alkyl, —O-lower alkyl, halogen, carboxyl, —CO 2 -lower alkyl and carbamoyl.
11. The method according to claim 10 , wherein R 1 is phenyl substituted with at least three halogens.
12. The method according to claim 11 , wherein R 2 is optionally substituted piperazino.
13. The method according to claim 11 , wherein R 2 is optionally substituted piperidino.
14. The method of claim 1 , wherein said administering is oral.
15. The method of claim 1 , wherein said administering is parenteral.
16. The compound according to claim 10 , wherein R 1 is phenyl substituted with at least three halogens.
17. The compound according to claim 16 , wherein R 2 is optionally substituted piperazino.
18. The compound according to claim 16 , wherein R 2 is optionally substituted piperidino.
19. A fused pyrimidine compound represented by Formula (I) or a pharmaceutically acceptable salt thereof:
wherein A is
wherein the carbon atoms which form the structure A may be substituted with one or more group(s) selected from the group consisting of lower alkyl, —O-lower alkyl, halogen, carboxyl, —CO 2 -lower alkyl and carbamoyl;
—R 1 is a phenyl substituted with at least three halogens; and
—R 2 is an optionally substituted cycloamino.
20. The compound according to claim 19 , wherein R 2 is optionally substituted piperazino.
21. The compound according to claim 19 , wherein R 2 is optionally substituted piperidino.
22. A fused pyrimidine compound represented by Formula (I) or a pharmaceutically acceptable salt thereof:
wherein A is
wherein the carbon atoms which form the structure A may be substituted with one or more group(s) selected from the group consisting of lower alkyl, —O-lower alkyl, halogen, carboxyl, —CO 2 -lower alkyl and carbamoyl;
—R 1 is a phenyl substituted with at least one halogen; and
—R 2 is an optionally substituted cycloamino.